SPDR S&P Telecom (XTL) 59.49 $XTL
A Red Flag On The S&P 500 Index
Cerebro1 - at Seeking Alpha - Wed Jan 21, 4:01PM CST
XTL: 59.49 (+0.33), XLB: 51.44 (+0.43), XLP: 49.50 (-0.23), DBC: 18.30 (+0.20), SPY: 209.78 (+0.86), IEF: 107.18 (-0.36), XLY: 74.89 (+0.45), XLK: 42.65 (+0.27), XLU: 45.17 (-0.70), XLE: 82.04 (+1.70), XLV: 70.72 (+0.28)
XTL Biopharmaceuticals Annual General Meeting of Shareholders Appoints Two New Members to the Board of Directors
PR Newswire - Tue Dec 30, 11:23AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced that the Company's shareholders approved the appointment of two new members to the Board of Directors, Doron Turgeman and Shlomo Shalev.
XTL: 59.49 (+0.33), BCOM: 15.76 (unch), XTLB: 2.08 (-0.04)
SPDR S&P Telecom ETF announces quarterly distribution of $0.179
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:44PM CST
XTL: 59.49 (+0.33)
WTO IT trade deal on verge of collapse
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 2:33AM CST
PXQ: 35.11 (unch), ROM: 160.74 (+2.80), TLL: 54.44 (-1.41), CQQQ: 36.39 (+0.41), XSW: 97.06 (+0.43), QTEC: 44.20 (+0.37), PBS: 26.38 (+0.23), PTF: 40.07 (+0.30), FXL: 36.04 (+0.45), IYZ: 30.91 (+0.12), TECL: 150.75 (+2.80), TDIV: 28.44 (+0.22), XLK: 42.65 (+0.27), XSD: 85.30 (+0.53), IYW: 107.68 (+0.94), XTL: 59.49 (+0.33), SOXS: 11.88 (-0.30), LTL: 96.91 (+0.43), KWEB: 33.34 (+0.39), IGM: 105.15 (+0.85), REW: 51.64 (-0.82), SOXL: 143.99 (+3.00), QQQC: 22.20 (+0.17), FDN: 64.55 (+0.93), FCOM: 28.08 (+0.01), SMH: 56.39 (+0.33), SOXX: 95.43 (+0.67), TECS: 10.04 (-0.20), RYT: 93.11 (+0.73), PSCT: 51.78 (+0.40), SSG: 46.40 (-0.66), FTEC: 32.71 (+0.22), PSJ: 41.85 (+0.74), IGV: 96.57 (+1.32), PSI: 26.30 (-0.18), USD: 94.92 (+0.46), MTK: 103.74 (+1.00), VOX: 89.20 (+0.09), IGN: 37.85 (+0.29), VGT: 108.04 (+0.87)
XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets
PR Newswire - Mon Dec 08, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company" , a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that the Board of Directors has appointed two new members, Dr. Jonathan Schapiro and Dr. Dobroslav Melamed.
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
Sector Returns For November 2014
Brian Gilmartin, CFA - Seeking Alpha - Mon Dec 01, 3:58PM CST
Since so much of our earnings work is sector-related, here is a quick recap of sector returns for November ’14, both from the S&P 500 perspective and the SPDR perspective. Note: The first column is the S&P 500 sector return, per The...
XTL: 59.49 (+0.33), XLB: 51.44 (+0.43), XLP: 49.50 (-0.23), SPY: 209.78 (+0.86), XLY: 74.89 (+0.45), XLK: 42.65 (+0.27), XLI: 57.17 (+0.26), XLU: 45.17 (-0.70), XLF: 24.43 (-0.02), XLV: 70.72 (+0.28), XLE: 82.04 (+1.70)
XTL Biopharmaceuticals Provides Financial and Operational Update For the Third Quarter of 2014
PR Newswire - Mon Dec 01, 7:00AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company" , a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three- and nine-month periods ended September 30, 2014.
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
Market Outlook - Grinding Higher Economy And Stocks
Price Headley, CFA - Seeking Alpha - Mon Dec 01, 4:20AM CST
As is usually the case, Thanksgiving week proved to be a rather tepid one for stocks, with most of the trading crowd choosing to check out around the middle of the week. Volume for last week as about half the norm. Nevertheless, where we left off on...
XTL: 59.49 (+0.33), IYZ: 30.91 (+0.12), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), VXX: 30.97 (-0.38), DIA: 180.34 (+0.50), IWM: 121.53 (+0.72)
S&P 500 Weekly Earnings Update: Q3 '14 Earnings Were Strong; Q4 '14 Will Also Be Very Healthy (Despite Energy)
Brian Gilmartin, CFA - Seeking Alpha - Mon Nov 24, 6:28AM CST
Per Thomson Reuters, the “forward 4-quarter” estimate last week fell slightly to $126.48 from the previous week’s $126.64. The metrics as of 11/21/14’s close: SP 500: 2,063.50 P.E ratio: 16.3(x) PEG ratio: ...
XTL: 59.49 (+0.33), RXI: 89.58 (+0.50), KXI: 92.57 (-0.62), IYJ: 109.15 (+0.67), DBE: 17.43 (+0.30), XLB: 51.44 (+0.43), IYH: 149.63 (+0.84), IPS: 40.00 (-0.26), IPD: 39.17 (+0.18), IYM: 86.13 (+0.83), FXU: 24.58 (-0.17), XLU: 45.17 (-0.70), IYF: 90.01 (-0.04), XLV: 70.72 (+0.28), IYZ: 30.91 (+0.12), SPY: 209.78 (+0.86), XLK: 42.65 (+0.27), JJE: 10.42 (+0.25), XLI: 57.17 (+0.26), XLF: 24.43 (-0.02), IYW: 107.68 (+0.94)
U.S., China to liberalize tech trade
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 1:52AM CST
PXQ: 35.11 (unch), ROM: 160.74 (+2.80), TLL: 54.44 (-1.41), CQQQ: 36.39 (+0.41), XSW: 97.06 (+0.43), QTEC: 44.20 (+0.37), PBS: 26.38 (+0.23), PTF: 40.07 (+0.30), FXL: 36.04 (+0.45), IYZ: 30.91 (+0.12), TECL: 150.75 (+2.80), TDIV: 28.44 (+0.22), XLK: 42.65 (+0.27), XSD: 85.30 (+0.53), IYW: 107.68 (+0.94), XTL: 59.49 (+0.33), SOXS: 11.88 (-0.30), LTL: 96.91 (+0.43), KWEB: 33.34 (+0.39), IGM: 105.15 (+0.85), REW: 51.64 (-0.82), SOXL: 143.99 (+3.00), QQQC: 22.20 (+0.17), FDN: 64.55 (+0.93), FCOM: 28.08 (+0.01), SMH: 56.39 (+0.33), SOXX: 95.43 (+0.67), TECS: 10.04 (-0.20), RYT: 93.11 (+0.73), PSCT: 51.78 (+0.40), SSG: 46.40 (-0.66), FTEC: 32.71 (+0.22), PSJ: 41.85 (+0.74), IGV: 96.57 (+1.32), PSI: 26.30 (-0.18), USD: 94.92 (+0.46), MTK: 103.74 (+1.00), VOX: 89.20 (+0.09), IGN: 37.85 (+0.29), VGT: 108.04 (+0.87)
ETFs Slipping to Rank #5 this Earnings Season - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Mon Oct 27, 1:00PM CDT
Given weak corporate earnings and huge levels of stock market volatility, several ETFs have slipped to Zacks ETF Rank of 5.
XTL: 59.49 (+0.33), BJK: 40.01 (+0.69), IHI: 117.25 (+0.94)
Biotechs are running circles around internet stocks
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 8:44AM CDT
PXQ: 35.11 (unch), ROM: 160.74 (+2.80), TLL: 54.44 (-1.41), XBI: 203.40 (+1.36), IBB: 323.46 (+3.04), XSW: 97.06 (+0.43), QTEC: 44.20 (+0.37), PBS: 26.38 (+0.23), PTF: 40.07 (+0.30), FXL: 36.04 (+0.45), IYZ: 30.91 (+0.12), TECL: 150.75 (+2.80), BBH: 122.45 (+0.86), XLK: 42.65 (+0.27), TDIV: 28.44 (+0.22), XSD: 85.30 (+0.53), IYW: 107.68 (+0.94), XTL: 59.49 (+0.33), SOXS: 11.88 (-0.30), PBE: 52.78 (+0.30), LTL: 96.91 (+0.43), IGM: 105.15 (+0.85), FBT: 110.21 (+1.02), REW: 51.64 (-0.82), SOXL: 143.99 (+3.00), FDN: 64.55 (+0.93), FCOM: 28.08 (+0.01), SMH: 56.39 (+0.33), SOXX: 95.43 (+0.67), TECS: 10.04 (-0.20), RYT: 93.11 (+0.73), PSCT: 51.78 (+0.40), SSG: 46.40 (-0.66), FTEC: 32.71 (+0.22), PSJ: 41.85 (+0.74), IGV: 96.57 (+1.32), PSI: 26.30 (-0.18), USD: 94.92 (+0.46), MTK: 103.74 (+1.00), VOX: 89.20 (+0.09), IGN: 37.85 (+0.29), VGT: 108.04 (+0.87)
The Complete Guide to Telecom ETFs - ETF News And Commentary
Zacks Equity Research - ZACKS - Tue Sep 30, 11:06AM CDT
Growing demand for technically superior products has been the silver lining for the telecom industry in an otherwise tough environment.
XTL: 59.49 (+0.33), IYZ: 30.91 (+0.12), VOX: 89.20 (+0.09), IXP: 63.80 (+0.02)
XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014
PR Newswire - Tue Sep 02, 11:09AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company" , a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three and six month periods ended June 30, 2014.
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity
PR Newswire - Wed Jul 16, 8:18AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company" , a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that an overview of its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE) is included in an article titled, Novel Approaches to the Development of Targeted Therapeutic Agents for Systemic Lupus Erythematosus. The article was written by Zev Sthoeger, Amir Sharabi and Edna Mozes. The article has been published in the Journal of Autoimmunity.
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements
PR Newswire - Thu Jun 12, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company" , a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that it received a letter from the Nasdaq Stock Market LLC ("Nasdaq" dated June 9, 2014 relating to the May 19, 2014 resignation of director Marc Allouche.
XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
A Red Flag On The S&P 500 Index
Cerebro1 - at Seeking Alpha - Wed Jan 21, 4:01PM CST
XTL: 59.49 (+0.33), XLB: 51.44 (+0.43), XLP: 49.50 (-0.23), DBC: 18.30 (+0.20), SPY: 209.78 (+0.86), IEF: 107.18 (-0.36), XLY: 74.89 (+0.45), XLK: 42.65 (+0.27), XLU: 45.17 (-0.70), XLE: 82.04 (+1.70), XLV: 70.72 (+0.28)
XTL Biopharmaceuticals Annual General Meeting of Shareholders Appoints Two New Members to the Board of Directors
PR Newswire - Tue Dec 30, 11:23AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced that the Company's shareholders approved the appointment of two new members to the Board of Directors, Doron Turgeman and Shlomo Shalev. XTL: 59.49 (+0.33), BCOM: 15.76 (unch), XTLB: 2.08 (-0.04)
SPDR S&P Telecom ETF announces quarterly distribution of $0.179
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:44PM CST
XTL: 59.49 (+0.33)
WTO IT trade deal on verge of collapse
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 2:33AM CST
PXQ: 35.11 (unch), ROM: 160.74 (+2.80), TLL: 54.44 (-1.41), CQQQ: 36.39 (+0.41), XSW: 97.06 (+0.43), QTEC: 44.20 (+0.37), PBS: 26.38 (+0.23), PTF: 40.07 (+0.30), FXL: 36.04 (+0.45), IYZ: 30.91 (+0.12), TECL: 150.75 (+2.80), TDIV: 28.44 (+0.22), XLK: 42.65 (+0.27), XSD: 85.30 (+0.53), IYW: 107.68 (+0.94), XTL: 59.49 (+0.33), SOXS: 11.88 (-0.30), LTL: 96.91 (+0.43), KWEB: 33.34 (+0.39), IGM: 105.15 (+0.85), REW: 51.64 (-0.82), SOXL: 143.99 (+3.00), QQQC: 22.20 (+0.17), FDN: 64.55 (+0.93), FCOM: 28.08 (+0.01), SMH: 56.39 (+0.33), SOXX: 95.43 (+0.67), TECS: 10.04 (-0.20), RYT: 93.11 (+0.73), PSCT: 51.78 (+0.40), SSG: 46.40 (-0.66), FTEC: 32.71 (+0.22), PSJ: 41.85 (+0.74), IGV: 96.57 (+1.32), PSI: 26.30 (-0.18), USD: 94.92 (+0.46), MTK: 103.74 (+1.00), VOX: 89.20 (+0.09), IGN: 37.85 (+0.29), VGT: 108.04 (+0.87)
XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets
PR Newswire - Mon Dec 08, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that the Board of Directors has appointed two new members, Dr. Jonathan Schapiro and Dr. Dobroslav Melamed. XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
Sector Returns For November 2014
Brian Gilmartin, CFA - Seeking Alpha - Mon Dec 01, 3:58PM CST
Since so much of our earnings work is sector-related, here is a quick recap of sector returns for November ’14, both from the S&P 500 perspective and the SPDR perspective. Note: The first column is the S&P 500 sector return, per The...
XTL: 59.49 (+0.33), XLB: 51.44 (+0.43), XLP: 49.50 (-0.23), SPY: 209.78 (+0.86), XLY: 74.89 (+0.45), XLK: 42.65 (+0.27), XLI: 57.17 (+0.26), XLU: 45.17 (-0.70), XLF: 24.43 (-0.02), XLV: 70.72 (+0.28), XLE: 82.04 (+1.70)
XTL Biopharmaceuticals Provides Financial and Operational Update For the Third Quarter of 2014
PR Newswire - Mon Dec 01, 7:00AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three- and nine-month periods ended September 30, 2014. XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
Market Outlook - Grinding Higher Economy And Stocks
Price Headley, CFA - Seeking Alpha - Mon Dec 01, 4:20AM CST
As is usually the case, Thanksgiving week proved to be a rather tepid one for stocks, with most of the trading crowd choosing to check out around the middle of the week. Volume for last week as about half the norm. Nevertheless, where we left off on...
XTL: 59.49 (+0.33), IYZ: 30.91 (+0.12), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), VXX: 30.97 (-0.38), DIA: 180.34 (+0.50), IWM: 121.53 (+0.72)
S&P 500 Weekly Earnings Update: Q3 '14 Earnings Were Strong; Q4 '14 Will Also Be Very Healthy (Despite Energy)
Brian Gilmartin, CFA - Seeking Alpha - Mon Nov 24, 6:28AM CST
Per Thomson Reuters, the “forward 4-quarter” estimate last week fell slightly to $126.48 from the previous week’s $126.64. The metrics as of 11/21/14’s close: SP 500: 2,063.50 P.E ratio: 16.3(x) PEG ratio: ...
XTL: 59.49 (+0.33), RXI: 89.58 (+0.50), KXI: 92.57 (-0.62), IYJ: 109.15 (+0.67), DBE: 17.43 (+0.30), XLB: 51.44 (+0.43), IYH: 149.63 (+0.84), IPS: 40.00 (-0.26), IPD: 39.17 (+0.18), IYM: 86.13 (+0.83), FXU: 24.58 (-0.17), XLU: 45.17 (-0.70), IYF: 90.01 (-0.04), XLV: 70.72 (+0.28), IYZ: 30.91 (+0.12), SPY: 209.78 (+0.86), XLK: 42.65 (+0.27), JJE: 10.42 (+0.25), XLI: 57.17 (+0.26), XLF: 24.43 (-0.02), IYW: 107.68 (+0.94)
U.S., China to liberalize tech trade
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 1:52AM CST
PXQ: 35.11 (unch), ROM: 160.74 (+2.80), TLL: 54.44 (-1.41), CQQQ: 36.39 (+0.41), XSW: 97.06 (+0.43), QTEC: 44.20 (+0.37), PBS: 26.38 (+0.23), PTF: 40.07 (+0.30), FXL: 36.04 (+0.45), IYZ: 30.91 (+0.12), TECL: 150.75 (+2.80), TDIV: 28.44 (+0.22), XLK: 42.65 (+0.27), XSD: 85.30 (+0.53), IYW: 107.68 (+0.94), XTL: 59.49 (+0.33), SOXS: 11.88 (-0.30), LTL: 96.91 (+0.43), KWEB: 33.34 (+0.39), IGM: 105.15 (+0.85), REW: 51.64 (-0.82), SOXL: 143.99 (+3.00), QQQC: 22.20 (+0.17), FDN: 64.55 (+0.93), FCOM: 28.08 (+0.01), SMH: 56.39 (+0.33), SOXX: 95.43 (+0.67), TECS: 10.04 (-0.20), RYT: 93.11 (+0.73), PSCT: 51.78 (+0.40), SSG: 46.40 (-0.66), FTEC: 32.71 (+0.22), PSJ: 41.85 (+0.74), IGV: 96.57 (+1.32), PSI: 26.30 (-0.18), USD: 94.92 (+0.46), MTK: 103.74 (+1.00), VOX: 89.20 (+0.09), IGN: 37.85 (+0.29), VGT: 108.04 (+0.87)
ETFs Slipping to Rank #5 this Earnings Season - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Mon Oct 27, 1:00PM CDT
Given weak corporate earnings and huge levels of stock market volatility, several ETFs have slipped to Zacks ETF Rank of 5.
XTL: 59.49 (+0.33), BJK: 40.01 (+0.69), IHI: 117.25 (+0.94)
Biotechs are running circles around internet stocks
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 8:44AM CDT
PXQ: 35.11 (unch), ROM: 160.74 (+2.80), TLL: 54.44 (-1.41), XBI: 203.40 (+1.36), IBB: 323.46 (+3.04), XSW: 97.06 (+0.43), QTEC: 44.20 (+0.37), PBS: 26.38 (+0.23), PTF: 40.07 (+0.30), FXL: 36.04 (+0.45), IYZ: 30.91 (+0.12), TECL: 150.75 (+2.80), BBH: 122.45 (+0.86), XLK: 42.65 (+0.27), TDIV: 28.44 (+0.22), XSD: 85.30 (+0.53), IYW: 107.68 (+0.94), XTL: 59.49 (+0.33), SOXS: 11.88 (-0.30), PBE: 52.78 (+0.30), LTL: 96.91 (+0.43), IGM: 105.15 (+0.85), FBT: 110.21 (+1.02), REW: 51.64 (-0.82), SOXL: 143.99 (+3.00), FDN: 64.55 (+0.93), FCOM: 28.08 (+0.01), SMH: 56.39 (+0.33), SOXX: 95.43 (+0.67), TECS: 10.04 (-0.20), RYT: 93.11 (+0.73), PSCT: 51.78 (+0.40), SSG: 46.40 (-0.66), FTEC: 32.71 (+0.22), PSJ: 41.85 (+0.74), IGV: 96.57 (+1.32), PSI: 26.30 (-0.18), USD: 94.92 (+0.46), MTK: 103.74 (+1.00), VOX: 89.20 (+0.09), IGN: 37.85 (+0.29), VGT: 108.04 (+0.87)
The Complete Guide to Telecom ETFs - ETF News And Commentary
Zacks Equity Research - ZACKS - Tue Sep 30, 11:06AM CDT
Growing demand for technically superior products has been the silver lining for the telecom industry in an otherwise tough environment.
XTL: 59.49 (+0.33), IYZ: 30.91 (+0.12), VOX: 89.20 (+0.09), IXP: 63.80 (+0.02)
XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014
PR Newswire - Tue Sep 02, 11:09AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three and six month periods ended June 30, 2014. XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity
PR Newswire - Wed Jul 16, 8:18AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that an overview of its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE) is included in an article titled, Novel Approaches to the Development of Targeted Therapeutic Agents for Systemic Lupus Erythematosus. The article was written by Zev Sthoeger, Amir Sharabi and Edna Mozes. The article has been published in the Journal of Autoimmunity. XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements
PR Newswire - Thu Jun 12, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that it received a letter from the Nasdaq Stock Market LLC ("Nasdaq" dated June 9, 2014 relating to the May 19, 2014 resignation of director Marc Allouche. XTL: 59.49 (+0.33), XTLB: 2.08 (-0.04)
